INmune Bio saw its stock surge 75% in after-hours trading Thursday after disclosing plans to unveil topline results from its Phase 2 Alzheimer’s trial on Monday. The company will present findings from ...

Asher Bio Presents New Data Demonstrating Preclinical Proof-of-Concept for AB359, a Highly Selective CD8-Targeted IL-2 Therapy, for Chronic Hepatitis B (HBV) at AASLD 2022 November 04, 2022 08:00 ...

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflamma Zura Bio Presents Data for the ...

These data were presented by Aimee Payne, M.D., Ph.D., Co-founder of and Scientific Advisory Board Co-chair at Cabaletta Bio in the ‘Science Breakthroughs’ session at the 2025 annual meeting ...

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy ...

LatchBio's goal is to give researchers a simple, integrated tool that can analyze bio data without hiring a computer scientist. Skip to main content Events Video Special Issues Jobs ...

Atavistik Bio Presents Preclinical Data on Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor, at EORTC-NCI-AACR Symposium ...

Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss PR Newswire DURHAM, N.C. and BEIJING ...

But the rich data set Google had to work with around protein folding has turned out to be an exception, not a rule. At BIO 2025 in Boston today, ...